Licensing deal
DelSiTech Ltd of Turku, Finland, and Bayer Innovation GmbH have entered a licence agreement giving Bayer the exclusive rights to use DelSiTech’s drug delivery technology in the fields of wound care and certain other applications.
DelSiTech will receive a signing fee, milestone payments and royalties on sales. The agreement contains also an option for further collaboration.
The DelSiTech drug delivery technology is a result of a cross-disciplinary project including researchers from the University of Turku and the Swedish-speaking University in Turku, Åbo Akademi.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
